Serum institute to sell Covishield to private hospitals at Rs 600 per dose

The Serum Institute of India said on Wednesday it would sell the AstraZeneca vaccine to the country's state governments at 400 rupees per dose and to private hospitals at Rs 600 rupees

Covishield
Covishield (Photo: PTI)
Reuters NEW DELHI
1 min read Last Updated : Apr 21 2021 | 1:05 PM IST

NEW DELHI (Reuters) - The Serum Institute of India said on Wednesday it would sell the AstraZeneca vaccine to the country's state governments at 400 rupees ($5.30) per dose and to private hospitals at 600 rupees ($7.95).

"Furthermore, owing to the complexity, and urgency of the situation it is challenging to supply it independently to each corporate entity," it said in a statement. "We would urge all corporate and private individuals to access the vaccines through the state facilitated machinery and private health systems."

($1 = 75.4620 Indian rupees)

 

(Reporting by Krishna N. Das and Euan Rocha, editing by Louise Heavens)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusSerum Institute of IndiaCoronavirus Vaccine

First Published: Apr 21 2021 | 1:02 PM IST

Next Story